Cortex Pharmaceuticals, Inc. Files December 31, 2014 Annual Report on Form … – Nasdaq

Nasdaq
The Company incurred a net loss attributable to common stockholders of $12,768,307 for the year ended December 31, 2014 (including adjustments related to the Series G 1.5% Convertible Preferred Stock of $10,060,772), reflecting a net loss per share of

and more

…read more

Scroll to Top